Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Investigating the place of JAK inhibitors in the treatment of myelofibrosis

Jeanne Palmer • 29 Sep 2022
SOHO 2022
Myelofibrosis Myeloproliferative Neoplasms

Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, highlights the importance of determining how to use novel JAK inhibitors in myelofibrosis (MF), discussing treatment sequencing, JAK inhibitor choice, and lines of therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jeanne Palmer

1:12
Strategies to improve the quality of life of patients with MPNs
Jeanne Palmer • 29 Sep 2022
1:12
Understanding the impact of therapies on treatment-emergent mutations in MF to prevent progression
Jeanne Palmer • 29 Sep 2022
1:31
Promising agents under investigation for the treatment of myelofibrosis with cytopenia
Jeanne Palmer • 29 Sep 2022
3:36
The role of allogeneic transplant in myelofibrosis and important factors to consider
Jeanne Palmer • 27 Aug 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals